Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 37Carcinoma, Non-Small-Cell Lung 23Uterine Cervical Neoplasms 22Melanoma 22Carcinoma, Renal Cell 18Endometrial Neoplasms 16Colorectal Neoplasms 15Carcinoma, Transitional Cell 15Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Pancreatic Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Carcinoma, Ovarian Epithelial 8Carcinoma, Merkel Cell 8Small Cell Lung Carcinoma 7Prostatic Neoplasms 7Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma 4Carcinosarcoma 4Vulvar Neoplasms 3

Interventions

Radiotherapy 11Brachytherapy 8fludarabine 5Radiation 5Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5Cyclophosphamide 5aldesleukin 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Cisplatin 4fludarabine phosphate 3durvalumab 3Vaccines, Synthetic 3Radiosurgery 3Papillomavirus Vaccines 3Paclitaxel 3Methods 3Early Intervention, Educational 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tremelimumab 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Topotecan 2Therapeutics 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Platinum 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Nivolumab × Gynecologic × Clear all
NCT06638931 2026-04-15

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
28 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡